参考资料:
1. Zhang L. Hepatitis A vaccination. Human Vaccines & Immunotherapeutics, 2020, 16(7): 1565-1573.
2. Peetermans J. Production, quality control and characterization of an inactivated hepatitis A vaccine. Vaccine, 1992, 10(Suppl 1): S99–101.
3. Armstrong ME, Giesa PA, Davide JP, et al. Development of the formalin-inactivated hepatitis A vaccine, VAQTATM from the live attenuated virus strain CR326F. J Hepatol, 1993, 18(Suppl 2): S20–26.
4. Vidor E, Fritzell B, Plotkin S. Clinical development of a new inactivated hepatitis A vaccine. Infection, 1996, 24(6): 447–58.
5. Ambrosch F, Wiedermann G, Jonas S, et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine, 1997, 15(11): 1209–13.
6. 陈娅娅. 甲肝灭活疫苗和减毒活疫苗的特点与区别. 中外健康文摘, 2012, 9(40): 92-93.
7. WHO position paper on hepatitis A vaccines - June 2012.
8. 许涤沙, 等. 中国2016年疑似预防接种异常反应监测数据分析, 中国疫苗和免疫, 2018,24(3): 299-309,322.
9. Guerra FA, Gress J, Werzberger A, et al. Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children. Pediatric Infectious Disease Journal, 2006, 25(10): 912-919.
10. Usonis V, Meriste S, Bakasenas V, et al. Immunogenicity and safety of a combined hepatitis A and B vaccine administered concomitantly with either a measles-mumps-rubella or a diphtheriatetanus-acellular pertussisinactivated poliomyelitis vaccine mixed with a Haemophilus influenzae type b conjugate vaccine in infants aged 12–18 months. Vaccine, 2005, 23: 2602–2606.
11. 国家免疫规划疫苗儿童免疫程序及说明 http://www.nhc.gov.cn/jkj/s3581/202103/590a8c7915054aa682a8d2ae8199e222.shtml
12. Zheng H, et al. Comparing live attenuated and inactivated hepatitis A vaccines: An immunogenicity study after one single dose. Vaccine, 2011, 29(48): 9098-9103.
13. 任银海, 吴文婷, 张玉成, 等. 孩尔来福甲型肝炎灭活疫苗小剂量免疫效果研究. 中国计划免疫, 2003, 9(2):114-116.
14. Andre FE, D’Hondt E, Delem A, et al. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings. Vaccine 1992; 10 Suppl 1:S160-S168.
15. 徐志一. 甲型肝炎减毒活疫苗保护效果与应用策略研究. 中华流行病学杂志, 2002, 23(5): 394-396.
16. 汪萱怡, 马景臣, 徐志一, 等. 甲型肝炎减毒活疫苗暴露后预防效果的观察. 中华医学杂志, 2002, 82(014): 955-957.
17. Wang Y, Qi Y, Xu W, et al. Immunogenicity persistence in children of hepatitis A vaccines Healive® and Havrix®: 11 years follow-up and long-term prediction. Hum Vaccin Immunother, 2020, 16(10): 2559-2564.
18. Zhuang F C , Mao Z A , Jiang L M , et al. [Long-term immunogenicity and effectiveness of live attenuated hepatitis A vaccine (H2-strain)-a study on the result of 15 years' follow up].[J]. Zhonghua Liu Xing Bing Xue Za Zhi, 2010, 31(12):1332-1335.
19. 甲型肝炎灭活疫苗(人二倍体细胞)说明书.
20. 冻干甲型肝炎减毒活疫苗说明书
21.https://www.who.int/zh/news-room/fact-sheets/detail/hepatitis-a
22. https://pubmed.ncbi.nlm.nih.gov/34345993/